AZD9833

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerBreast Carcinoma

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Cymbalta

Alnylam Pharmaceuticals

Preclinical

32

AZD9833

AstraZeneca

Phase 2

53

Recentin

NNational Cancer Institute (NCI)

Preclinical

24

Chantix

PPrism Pharmaceuticals

Preclinical

15

Avastin

Roche

Preclinical

46

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Preclinical

17

Gadolinium-Chelate

MM.D. Anderson Cancer Center

Preclinical

18

Docetaxel-Carboplatin

NNational University Hospital, Singapore

Preclinical

19

Combination NRT

UUniversity of Alabama at Birmingham

Preclinical

110

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1Show 5 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer5 trials

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Completed·AstraZeneca·Phase 1·NCT04541433·10 enrolled

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Active, not recruiting·AstraZeneca·Phase 2·NCT04214288·240 enrolled

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Active, not recruiting·AstraZeneca·Phase 3·NCT04711252·1,370 enrolled

Show 2 more trials

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Completed·AstraZeneca·Phase 2·NCT04588298·135 enrolled

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Active, not recruiting·AstraZeneca·Phase 1·NCT03616587·396 enrolled

CDK4/6 Inhibitor1 trial

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Active, not recruiting·AstraZeneca·Phase 3·NCT04964934·315 enrolled

Midazolam1 trial

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Completed·AstraZeneca·Phase 1·NCT05438303·59 enrolled

Tics1 trial

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

Completed·AstraZeneca·Phase 1·NCT04546347·32 enrolled

Recovery1 trial

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

Completed·AstraZeneca·Phase 1·NCT05364255·6 enrolled

1 more indication

Unspecified1 trial

AZD9833 China PK Study

Completed·AstraZeneca·Phase 1·NCT04818632·28 enrolled

Details

Drug Info

Related News